Integer Holdings Co. (NYSE:ITGR) Given Consensus Rating of “Moderate Buy” by Brokerages

Integer Holdings Co. (NYSE:ITGR) has been given an average rating of “Moderate Buy” by the six analysts that are covering the firm, MarketBeat Ratings reports. Two analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $120.50.

ITGR has been the topic of several recent research reports. CL King started coverage on Integer in a report on Thursday, March 14th. They set a “buy” rating and a $137.00 price objective on the stock. Benchmark lifted their price objective on Integer from $105.00 to $130.00 and gave the company a “buy” rating in a research report on Thursday, March 28th. Bank of America upgraded Integer from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $105.00 to $135.00 in a research report on Monday, April 15th. Finally, KeyCorp lifted their price objective on Integer from $123.00 to $139.00 and gave the company an “overweight” rating in a research report on Tuesday, April 9th.

Institutional Investors Weigh In On Integer

A number of institutional investors and hedge funds have recently made changes to their positions in the company. BlackRock Inc. grew its stake in shares of Integer by 0.6% during the first quarter. BlackRock Inc. now owns 6,018,773 shares of the medical equipment provider’s stock worth $484,933,000 after purchasing an additional 38,664 shares during the period. Vanguard Group Inc. grew its stake in Integer by 0.4% in the third quarter. Vanguard Group Inc. now owns 3,843,992 shares of the medical equipment provider’s stock valued at $301,484,000 after acquiring an additional 15,300 shares during the period. Victory Capital Management Inc. grew its stake in Integer by 8.9% in the third quarter. Victory Capital Management Inc. now owns 1,632,549 shares of the medical equipment provider’s stock valued at $128,041,000 after acquiring an additional 133,898 shares during the period. State Street Corp grew its stake in Integer by 1.6% in the second quarter. State Street Corp now owns 1,356,627 shares of the medical equipment provider’s stock valued at $120,211,000 after acquiring an additional 21,795 shares during the period. Finally, Macquarie Group Ltd. grew its stake in Integer by 0.3% in the first quarter. Macquarie Group Ltd. now owns 972,726 shares of the medical equipment provider’s stock valued at $75,386,000 after acquiring an additional 3,361 shares during the period. Institutional investors own 99.29% of the company’s stock.

Integer Price Performance

Shares of NYSE:ITGR opened at $116.62 on Friday. Integer has a 1-year low of $69.40 and a 1-year high of $121.53. The firm has a market capitalization of $3.91 billion, a PE ratio of 43.35, a PEG ratio of 1.63 and a beta of 1.10. The business’s 50 day moving average is $111.82 and its 200-day moving average is $98.63. The company has a current ratio of 2.80, a quick ratio of 1.71 and a debt-to-equity ratio of 0.64.

Integer (NYSE:ITGR) last announced its quarterly earnings data on Thursday, February 15th. The medical equipment provider reported $1.39 earnings per share for the quarter, topping the consensus estimate of $1.34 by $0.05. Integer had a return on equity of 10.80% and a net margin of 5.68%. The company had revenue of $413.15 million for the quarter, compared to analyst estimates of $409.04 million. During the same quarter last year, the firm earned $1.11 EPS. Integer’s revenue for the quarter was up 10.9% compared to the same quarter last year. Sell-side analysts predict that Integer will post 5.31 earnings per share for the current year.

About Integer

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.